Login to Your Account



Regulatory Roundup

FDA Inhaler Instructions Doubts Cause Delay in UT's PAH Drug

By Donna Young


Tuesday, March 17, 2009
Shares of United Therapeutics Corp. fell 10 percent Monday after the Silver Spring, Md.-based firm said it expected a delay in the approval of Tyvaso (treprostinil), an inhaled version of the company's approved pulmonary arterial hypertension (PAH) drug Remodulin, an injectable drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription